Is Caribou Biosciences Inc. Common Stock a good investment? Caribou Biosciences Inc. Common Stock (CRBU) is currently trading at 0.3619 USD. Market analysts have a consensus price target of 5.00 USD. This suggests a potential upside from current levels.
Earnings Schedule: Caribou Biosciences Inc. Common Stock is expected to release its next earnings report on March 4, 2027. The market consensus estimate for Forward EPS is -0.90.
No, it does not currently pay a dividend.
Caribou Biosciences Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
The next earnings date is projected to be March 4, 2027. The company currently has a trailing EPS of -0.98.
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Community Discussion